mRNA Zeta Potential Analysis Service
Overview
In the rapidly evolving landscape of therapeutic nucleic acids, the success of messenger RNA (mRNA) vaccines is inextricably linked to the performance of their delivery vehicles, typically lipid nanoparticles (LNPs). A critical physicochemical parameter governing the stability, safety, and biological efficacy of these mRNA-LNP complexes is the zeta potential (ZP). ZP is the electrokinetic potential at the "slipping plane" of a particle in a colloidal dispersion, representing the net charge at the particle-liquid interface.
At CD BioGlyco, we recognize that precise ZP characterization is not merely a quality control (QC) checkbox but a fundamental requirement for optimizing mRNA structural integrity and delivery efficiency. A high-magnitude ZP provides sufficient electrostatic repulsion to prevent particle aggregation, ensuring a long shelf-life and consistent potency. Conversely, ZP measurements at physiological pH provide essential insights into the particle's interaction with cell membranes and its potential for endosomal escape. Our specialized mRNA ZP analysis service provides the high-resolution data needed to refine mRNA-LNP formulations from early-stage research through to large-scale manufacturing.
Key Technologies
- Electrophoretic Light Scattering (ELS)
ELS is the primary technique used to determine electrophoretic mobility. When an electric field is applied to the mRNA-LNP suspension, the charged particles migrate toward the electrode of opposite charge. By measuring the frequency shift of the scattered laser light caused by this movement, we calculate the velocity and the ZP. - Phase Analysis Light Scattering (PALS)
For samples with low electrophoretic mobility or high ionic strength, we employ PALS. This technique measures the phase shift of the scattered light rather than the frequency shift, offering up to 100 times more sensitivity than traditional ELS. This ensures accurate measurements even for LNPs with near-neutral surface charges or in highly conductive environments.
Precision Charge Analysis for Superior mRNA Stability and Delivery
As a vital component of our therapeutic nucleic acid development platform, specifically under mRNA-based vaccine development and mRNA structural characterization, CD BioGlyco offers a comprehensive suite of analytical services. We provide deep-dive characterization that goes beyond basic value reporting to include:
- pH Titration & Isoelectric Point (pI) Determination
We analyze how ZP fluctuates across a range of pH values to identify the pI, which is crucial for understanding LNP stability during storage and its behavior in the acidic environment of the endosome. - Ionic Strength Influence Mapping
Evaluation of ZP under varying salt concentrations to simulate different physiological fluids and assess the shielding effect of counter-ions on the LNP surface. - Surface Modification Validation
Quantifying the impact of PEGylation, ligand conjugation, or specific lipid ratios on the final surface charge of the mRNA-LNP. - Thermal Stability Correlation
Monitoring ZP changes during temperature stress tests to predict long-term colloidal stability and potential degradation pathways.
Workflow
Sample Preparation and Buffer Optimization
We collaborate with clients to determine the optimal dilution and buffer conditions. Samples are carefully prepared to ensure the mRNA-LNP concentration falls within the linear detection range of our instruments.
Experimental Setup and Calibration
Our instruments undergo daily calibration using standards. We select the appropriate electrode type based on the sample's conductivity and volume to prevent electrode polarization or sample contamination.
Electrophoretic Mobility Measurement
Using ELS or PALS, we perform multiple runs to capture the Doppler or phase shift. This step involves precise temperature control to ensure viscosity remains constant, as ZP is highly temperature-dependent.
Mathematical Modeling and Calculation
The raw mobility data is converted to ZP using the Henry equation. We meticulously select the appropriate model based on the particle size and the thickness of the electrical double layer.
Quality Control and Data Validation
Our senior biophysicists review the data, checking for signal-to-noise ratios, polydispersity indices (PDI), and potential multi-modal charge distributions that might indicate a heterogeneous particle population or free mRNA.
Comprehensive Reporting and Interpretation
Clients receive a detailed technical report including raw data, ZP distribution plots, mean values, and expert interpretation of what the results imply for the formulation's stability and biological performance.
Applications
Vaccine Formulation Optimization
ZP analysis is used to screen ionizable lipid ratios, ensuring the mRNA is fully encapsulated, and the particle surface maintains a charge profile that balances stability with low toxicity.
Stability and Shelf-life Prediction
By monitoring ZP over time and across temperature gradients, researchers predict the likelihood of LNP aggregation and establish robust storage conditions for mRNA therapeutics.
Delivery Vehicle Engineering
Developers of targeted mRNA therapies use ZP analysis to verify the successful attachment of targeting ligands or to engineer pH-responsive surface charges for enhanced endosomal escape.
Quality Control
As a critical quality attribute (CQA), ZP data is essential for ensuring batch-to-batch consistency during the scale-up of vaccine manufacturing.
Advantages
Expert Data Interpretation
Our team consists of Ph.D.-level scientists with deep expertise in mRNA-LNP biophysics, providing insights that go far beyond raw data to solve complex formulation challenges.
High-Throughput Capabilities
We utilize automated sample handling systems to provide rapid turnaround times without sacrificing the rigor of individual measurements, accelerating your development timelines significantly.
Minimal Sample Consumption
Our optimized protocols require very small sample volumes, which is critical when working with high-value or early-stage mRNA materials.
Comprehensive Customization
Whether you require pH titration, temperature ramping, or analysis in complex biological media, we tailor every project to your specific research.
Frequently Asked Questions
Customer Review
The ZP analysis provided by CD BioGlyco was instrumental in our recent LNP optimization project. Their ability to perform pH titrations in complex buffers allowed us to pinpoint the exact pI of our candidate vaccines, leading to a 40% improvement in stability. The technical report was thorough and ready for regulatory submission.
— S.T., Biopharmaceutical Research Institute
We struggled with batch-to-batch variation in our mRNA-LNP surface charge until we partnered with CD BioGlyco. Their PALS technology offered a level of resolution we couldn't achieve in-house, and their team's interpretation helped us refine our PEGylation strategy.
— Z.T., Emerging Biotech
Fast, reliable, and highly professional. CD BioGlyco's mRNA structural characterization services have become a standard part of our quality control pipeline for all our therapeutic nucleic acid leads.
— A.E., Vaccine Development Center
Associated Services
CD BioGlyco offers a premier mRNA ZP analysis service designed to provide critical insights into the surface charge and stability of mRNA delivery systems. By integrating advanced ELS/PALS technologies with deep biological expertise, we help our clients ensure the safety, stability, and efficacy of their mRNA-based therapeutics. Please feel free to contact us to elevate your mRNA vaccine development.
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform